Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Cited In for PubMed (Select 2413547)

1.

Endoscopic ultrasound-guided therapies in pancreatic neoplasms.

Yang D, DiMaio CJ.

Biomed Res Int. 2015;2015:731049. doi: 10.1155/2015/731049. Epub 2015 Jan 31. Review.

2.

Etanercept biosimilars.

Azevedo VF, Galli N, Kleinfelder A, D'Ippolito J, Urbano PC.

Rheumatol Int. 2015 Feb;35(2):197-209. doi: 10.1007/s00296-014-3080-5. Epub 2014 Jul 1.

3.

NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells.

Zhang J, Wu H, Li P, Zhao Y, Liu M, Tang H.

J Transl Med. 2014 Jun 1;12:155. doi: 10.1186/1479-5876-12-155.

4.

Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations.

Kienle GS.

Glob Adv Health Med. 2012 Mar;1(1):92-100. doi: 10.7453/gahmj.2012.1.1.016. Review.

5.

Zn- and Mg- containing tricalcium phosphates-based adjuvants for cancer immunotherapy.

Wang X, Li X, Onuma K, Sogo Y, Ohno T, Ito A.

Sci Rep. 2013;3:2203. doi: 10.1038/srep02203.

6.

Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Roberts CK, Hevener AL, Barnard RJ.

Compr Physiol. 2013 Jan;3(1):1-58. doi: 10.1002/cphy.c110062. Review.

7.

Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?

Leal MC, Casabona JC, Puntel M, Pitossi FJ.

Front Cell Neurosci. 2013 Apr 29;7:53. doi: 10.3389/fncel.2013.00053. eCollection 2013.

8.

Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Aggarwal BB, Gupta SC, Sung B.

Br J Pharmacol. 2013 Aug;169(8):1672-92. doi: 10.1111/bph.12131. Review.

9.

Lipopolysaccharide treatment suppresses spontaneously developing ankylosing enthesopathy in B10.BR male mice: the potential role of interleukin-10.

Capkova J, Hrncir T, Kubatova A, Tlaskalova-Hogenova H.

BMC Musculoskelet Disord. 2012 Jun 21;13:110. doi: 10.1186/1471-2474-13-110.

10.

Adaptation of BHK cells producing a recombinant protein to serum-free media and protein-free medium.

Cruz HJ, Moreira JL, Stacey G, Dias EM, Hayes K, Looby D, Griffiths B, Carrondo MJ.

Cytotechnology. 1998 Jan;26(1):59-64. doi: 10.1023/A:1007951813755.

11.

Recognition of human tumor necrosis factor α (TNF-α) by therapeutic antibody fragment: energetics and structural features.

Marušič J, Podlipnik Č, Jevševar S, Kuzman D, Vesnaver G, Lah J.

J Biol Chem. 2012 Mar 9;287(11):8613-20. doi: 10.1074/jbc.M111.318451. Epub 2012 Jan 19.

12.

EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.

Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, Hanna N, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M.

Gastrointest Endosc. 2012 Feb;75(2):332-8. doi: 10.1016/j.gie.2011.10.007.

13.

Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis factor-α production in lipopolysaccharide-injected mice, resulting in rescuing mice from death in vivo.

Shimo T, Adachi Y, Umezawa K, Okigaki M, Takaya J, Taniuchi S, Ikehara S, Kaneko K.

Clin Exp Immunol. 2011 Nov;166(2):299-306. doi: 10.1111/j.1365-2249.2011.04475.x. Erratum in: Clin Exp Immunol. 2012 Oct;170(1):114.

14.

Steering carbon nanotubes to scavenger receptor recognition by nanotube surface chemistry modification partially alleviates NFκB activation and reduces its immunotoxicity.

Gao N, Zhang Q, Mu Q, Bai Y, Li L, Zhou H, Butch ER, Powell TB, Snyder SE, Jiang G, Yan B.

ACS Nano. 2011 Jun 28;5(6):4581-91. doi: 10.1021/nn200283g. Epub 2011 Jun 1.

15.

Metabolic effects of obesity: A review.

Singla P, Bardoloi A, Parkash AA.

World J Diabetes. 2010 Jul 15;1(3):76-88. doi: 10.4239/wjd.v1.i3.76.

16.

Probing the mechanical properties of TNF-α stimulated endothelial cell with atomic force microscopy.

Lee SY, Zaske AM, Novellino T, Danila D, Ferrari M, Conyers J, Decuzzi P.

Int J Nanomedicine. 2011;6:179-95. doi: 10.2147/IJN.S12760. Epub 2011 Jan 24. Erratum in: Int J Nanomedicine. 2014;9:2567.

17.

A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK.

Oncology. 2010;79(5-6):382-8. doi: 10.1159/000323488. Epub 2011 Mar 25.

18.

Active immunotherapy induces antibody responses that target tumor angiogenesis.

Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G.

Cancer Res. 2010 Dec 15;70(24):10150-60. doi: 10.1158/0008-5472.CAN-10-1852.

19.

Metaxin deficiency alters mitochondrial membrane permeability and leads to resistance to TNF-induced cell killing.

Ono K, Wang X, Kim SO, Armstrong LC, Bornstein P, Han J.

Protein Cell. 2010 Feb;1(2):161-73. doi: 10.1007/s13238-010-0017-y. Erratum in: Protein Cell. 2010 Dec;1(12):1128.

20.

Mast cell stabilization improves survival by preventing apoptosis in sepsis.

Ramos L, Peña G, Cai B, Deitch EA, Ulloa L.

J Immunol. 2010 Jul 1;185(1):709-16. doi: 10.4049/jimmunol.1000273. Epub 2010 Jun 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk